首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   82491篇
  免费   7369篇
  国内免费   5496篇
耳鼻咽喉   847篇
儿科学   935篇
妇产科学   1232篇
基础医学   10630篇
口腔科学   1415篇
临床医学   10986篇
内科学   12474篇
皮肤病学   1031篇
神经病学   4517篇
特种医学   3245篇
外国民族医学   53篇
外科学   8554篇
综合类   10788篇
现状与发展   21篇
一般理论   22篇
预防医学   5143篇
眼科学   2992篇
药学   8498篇
  67篇
中国医学   4162篇
肿瘤学   7744篇
  2024年   261篇
  2023年   1222篇
  2022年   3186篇
  2021年   4105篇
  2020年   3013篇
  2019年   2892篇
  2018年   3082篇
  2017年   2548篇
  2016年   2644篇
  2015年   3806篇
  2014年   4728篇
  2013年   4178篇
  2012年   6184篇
  2011年   6619篇
  2010年   4115篇
  2009年   3119篇
  2008年   4298篇
  2007年   4170篇
  2006年   4258篇
  2005年   4096篇
  2004年   2777篇
  2003年   2541篇
  2002年   2091篇
  2001年   1799篇
  2000年   1775篇
  1999年   2060篇
  1998年   1343篇
  1997年   1312篇
  1996年   1000篇
  1995年   944篇
  1994年   806篇
  1993年   507篇
  1992年   596篇
  1991年   509篇
  1990年   482篇
  1989年   436篇
  1988年   393篇
  1987年   312篇
  1986年   263篇
  1985年   219篇
  1984年   137篇
  1983年   92篇
  1982年   52篇
  1981年   59篇
  1980年   39篇
  1979年   68篇
  1978年   28篇
  1977年   22篇
  1976年   20篇
  1974年   27篇
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
71.
目的:探讨中西医结合治疗宫颈糜烂的疗效。方法:以三黄洗剂加用龙血竭胶囊外用,并配合西药消炎治疗宫颈糜烂40例。结果:治愈35例,治愈率87.5%;好转5例,好转率12.5%。结论:中西医结合治疗宫颈糜烂具有良好的疗效。  相似文献   
72.
Recent studies have suggested that aldosterone plays a role in the pathogenesis of renal injury. In this study, we investigated whether local angiotensin II (Ang II) activity contributes to the progression of renal injury in aldosterone/salt-induced hypertensive rats. Uninephrectomized rats were treated with 1% NaCl in a drinking solution and one of the following combinations for 6 weeks: vehicle (2% ethanol, s.c.; n=9), aldosterone (0.75 mug/h, s.c.; n=8), aldosterone+Ang II type 1 receptor blocker olmesartan (10 mg/kg/day, p.o.; n=8), or aldosterone+olmesartan (100 mg/kg/day, p.o.; n=9). Aldosterone/salt-treated hypertensive rats exhibited severe proteinuria and renal injury characterized by glomerular sclerosis and tubulointerstitial fibrosis. Aldosterone/salt-induced renal injury was associated with augmented expression of angiotensin converting enzyme and Ang II levels in the renal cortex and medullary tissues. Renal cortical and medullary mRNA expression of transforming growth factor-beta (TGF-beta) and connective tissue growth factor (CTGF) as well as the collagen contents were increased in aldosterone/salt-treated hypertensive rats. Treatment with olmesartan (10 or 100 mg/kg/day) had no effect on blood pressure but attenuated proteinuria in a dose-dependent manner. Olmesartan at 10 mg/kg/day tended to decrease renal cortical and medullary Ang II levels, TGF-beta and CTGF expression, and collagen contents; however, these changes were not significant. On the other hand, an ultrahigh dose of olmesartan (100 mg/kg/day) significantly decreased these values and ameliorated renal injury. These data suggest that augmented local Ang II activity contributes, at least partially, to the progression of aldosterone/salt-dependent renal injury.  相似文献   
73.
Bhatia  G.  S.  Sosin  M.  D.  Patel  J.  V.  孙凯 《世界核心医学期刊文摘》2006,2(8):58-59
目的:本研究旨在明确左心室收缩功能障碍在临床类风湿病(RD)患者中是否较正常人群中更常见,并评价脑利钠肽(BNP)的诊断价值。背景:RD患者罹患缺血性心脏病的风险增加,而采用超声心动图评估RD患者心功能不全的大型研究却少见。假定左心室收缩功能障碍在RD患者中较正常人群中更为  相似文献   
74.
75.
BACKGROUND: Dendritic cell is the most major antigen presenting cell of organism. It is proved in recent studies that human umbilical cord blood mononuclear cells induced and cultured in vitro by recombinant human granulocyte-macrophage colony stimulating factor (rhG-MCSF) and recombinant human interleukin-4(rhIL-4) can generate a great many dendritic cells and promote the lethal effect of T cells on human neuroblastoma, but it is unclear that whether the lethal effect is associated with the most proper concentration of dendritic cells. OBJECTIVE: To investigate the lethal effect of human umbilical cord blood mononuclear cells induced in vitro by cytokines differentiating into dendritic cells on human neuroblastoma, and its best concentration range. DESIGN: Open experiment. SETTING: Department of Pediatrics, the Medical School Hospital of Qingdao University. MATERIALS: The study was carried out in the Shandong Provincial Key Laboratory (Laboratory for the Department of Pediatrics of the Medical School Hospital of Qingdao University) during September 2005 to May 2006. Human umbilical cord blood samples were taken from the healthy newborn infants of full-term normal delivery during October to November 2005 in the Medical School Hospital of Qingdao University, and were voluntarily donated by the puerperas. Main instruments: type 3111 CO2 incubator (Forma Scientific, USA), type 550 ELISA Reader (Bio-Rad, USA). Main reagents: neuroblastoma cell line SK-N-SH (Shanghai Institute of Life Science, Chinese Academy of Sciences), RPMI-1640 culture fluid and fetal bovine serum (Hyclone), rhIL-4 (Promega, USA), rhG-MCSF (Harbin Pharmaceutic Group Bioengineering Co.Ltd), rat anti-human CD1a monoclonal antibody and FITC-labeled rabbit anti-rat IgG (Xiehe Stem cell Gene Engineering Co.Ltd). METHODS: ① Human umbilical cord blood mononuclear cells obtained with attachment methods differentiated into human umbilical cord blood dendritic cells, presenting typical morphology of dendritic cells after in vitro induction by rhG-MCSF and rhIL-4. ② Different concentrations of dendritic cells[ dendritic cells: neuroblastoma cells=20∶1,50∶1,100∶1(2×108 L-1,5×108 L-1,1×109 L-1)], 1×109 L-1 T cells and 1×107 L-1 neuroblastoma cells were added in the experimental group. 1×109 L-1 T cells and 1×107 L-1 neuroblastoma cells were added in the control group. ③ Main surface marker CD1a molecules of dendritic cells were detected with indirect immunofluorescence, and the percent rate of dendritic cells was counted with ultraviolet light and expressed as the expression rate of CD1a+ cells. ④ Single effector cells and target cells were respectively set in the experimental group and control group to obtain the lethal effect. The lethal effect of dendritic cells on neuroblastoma cells was indirectly evaluated by detecting cellular survival with MTT assay. The lethal effect(%)=(1-A experimental well-A effector cell well/A target cell well)×100%.⑤The experimental data were presented as Mean ±SD, and paired t test was used. MAIN OUTCOME MEASURES: ① Morphological characters of dendritic cells in the process of induction and differentiation. ②CD1a+ cellular expression rate. ③Lethal effect of dendritic cells on neuroblastoma cells. RESULTS: ①Morphological characters of dendritic cells in the process of induction and differentiation: On the 15th day after human umbilical cord blood mononuclear cells were induced by rhG-MCSF and rhIL-4, typical morphology of dendritic cells could be seen under an inverted microscope. ②Expression rate of CD1a+ cells was (43.12±5.83)%. ③Lethal effect of dendritic cells on neuroblastoma cells: Lethal effect of dendritic cells stimulated T cells in each experimental group ( dendritic cells: neuroblastoma cells=100∶1,50∶1,20∶1 respectively) on neuroblastoma cells was significantly higher than that in control group[(31.00 ±4.41)%,(30.92±5.27)%,(33.57±5.35)%,(26.23±5.20)%, t=3.51,2.98,4.24, P < 0.01); But the lethal effect of dendritic cells on neuroblastoma was significantly lower when their ratio was 100∶1 and 50∶1 in comparison with 20:1 (t=2.01,2.36, P < 0.05), and no significant difference in lethal effect existed between the ratio at 100∶1 and 50∶1(t=0.06,P > 0.05). CONCLUSION: Dendritic cells differentiated from human umbilical cord blood mononuclear cells after in vitro induction of cytokines can promote the lethal effect of T cells on neuroblastoma cells. The lethal effect is associated with the concentration of dendritic cells within some range.  相似文献   
76.
77.
胸腰椎骨折术后内固定松动、断裂的原因及预防   总被引:14,自引:3,他引:11  
目的 探讨椎弓根螺钉系统用于胸腰椎骨折术后出现松动、断裂的原因,并提出相应的预防对策。方法 12例胸腰椎骨折术后内固定失效病例,采用RF系统3例,AF系统9例。均未行植骨融合,AF系统中未按要求安装横连结3例,术后伤椎前缘高度平均恢复至正常的85.2%。结果 术后8—21个月出现棒断裂4例,螺钉断裂3例,钉帽松动5例。结论 内固定物的自身问题、术者的经验欠缺及操作不规范是胸腰椎骨折术后椎弓根螺钉系统松动、断裂的原因,但伤椎骨结构未能得到良好重建及术后椎间盘退变可能是其更重要的因素。因此重视内固定物的选择、加强规范操作,强调对损伤椎体及椎间盘的全面处理是预防内固定失效的有效措施。  相似文献   
78.
79.
Glial glutamate transporter-1 (GLT-1) plays an essential role in removing glutamate from the extracellular space and maintaining the glutamate below neurotoxic level in the brain. To explore whether GLT-1 plays a role in the acquisition of brain ischemic tolerance (BIT) induced by cerebral ischemic preconditioning (CIP), the present study was undertaken to observe in vivo changes in the expression of GLT-1 and glial fibrillary acidic protein (GFAP) in the CA1 hippocampus during the induction of BIT, and the effect of dihydrokainate (DHK), an inhibitor of GLT-1, on the acquisition of BIT in rats. Immunohistochemistry for GFAP showed that the processes of astrocytes were prolonged after a CIP 2 days before the lethal ischemic insult, which could protect pyramidal neurons in the CA1 hippocampus against delayed neuronal death induced normally by lethal ischemic insult. The prolonged processes extended into the area between the pyramidal neurons and tightly surrounded them. These changes made the pyramidal layer look like a 'shape grid'. Simultaneously, the prolonged and extended processes showed a great deal of GLT-1. Western blotting analysis showed significant upregulation of GLT-1 expression after the CIP, especially when it was administered 2 days before the subsequent lethal ischemic insult. Neuropathological evaluation by thionin staining showed that DHK dose-dependently blocked the protective role of CIP against delayed neuronal death induced normally by lethal brain ischemia. It might be concluded that the surrounding of pyramidal neurons by astrocytes and upregulation of GLT-1 induced by CIP played an important role in the acquisition of the BIT induced by CIP.  相似文献   
80.
探讨keratin 13基因在喉癌发生中的作用。方法在keratin 13基因内部及附近选择5个微卫星引物进行LOH分析,于DNA水平间接检测100例喉癌患者中该基因的缺失情况。结果5个STR位点均存在LOH,其中D17S1964E、D17S2092、D17S791、D17S1665及D17S808位点的LOH频率分别为30.48%、26.02%、21.62%、37.66%和21.51%,以D17S1665位点的LOH频率最高,杂合性丢失与临床分期无显著相关。结论Keratin13基因在喉癌的发生中具有重要作用,具体机制有待进一步研究。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号